查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1586292

慢性特发性便秘治疗药物市场：按药物类别、给药途径、分销管道划分 - 全球预测 2025-2030

Chronic Idiopathic Constipation Therapeutic Market by Drug Class (Bulk-Forming Agents, Emollients, Laxatives), Route of Administration (Oral, Parenteral), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年慢性特发性便秘治疗药物市值为5.7325亿美元，预计2024年将达到6.1907亿美元，复合年增长率为8.08%，2030年将达到9.8796亿美元，预计将达到1000万美元。

慢性特发性便秘（CIC）药物市场的重点是旨在解决长期便秘但未确定根本原因的药物。这个市场包括各种药物干预措施，包括泻药、促动力剂以及旨在调节肠道和缓解症状的新联合疗法。对治疗 CIC 的药物的需求源于这种疾病的严重流行，它影响患者的生活品质并给医疗保健系统带来负担。应用主要是改善症状和预防併发症，胃肠病学家和基层医疗医生通常透过配方和患者管理来带头最终使用。主要成长动力包括人口老化，更容易患慢性便秘，以及药物配方的进步，提高了疗效和安全性。此外，认知度和诊断率的提高也对市场扩张做出了积极贡献。然而，利用生物技术进步开发客製化疗法存在潜在的商机，例如考虑遗传倾向的微生物调节疗法和个人化医疗方法。鼓励公司将研发工作重点放在创新的给药机制和联合治疗上，以提高患者的依从性并改善治疗结果。然而，市场成长受到严峻挑战的限制，例如严格的法律规范、高昂的研发成本以及现有药物仿单标示外使用的竞争。此外，医师对新治疗方法的认知较低也是市场渗透的限制因素。最好的创新领域包括开发副作用最小的非系统疗法以及即时监测患者症状以更好地调整药物的技术。 CIC 治疗市场充满活力，并受到监管政策、竞争性定价和塑造治疗药物范式的持续临床试验的高度影响。因此，市场格局需要药品製造商、医疗保健提供者和研究机构之间的策略合作，以加速创新突破并增强整体患者照护。

主要市场统计
基准年[2023] 57325万美元
预测年份 [2024] 61907万美元
预测年份 [2030] 98796万美元
复合年增长率（%） 8.08%

市场动态：揭示快速发展的慢性特发性便秘治疗市场的关键市场洞察

供需的动态交互作用正在改变慢性特发性便秘药物市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 生活方式和饮食的改变
    • 患者对非处方药的使用增加
    • 全球卫生支出增加
  • 市场限制因素
    • 对慢性特发性便秘的认知与诊断下降
  • 市场机会
    • 药物输送机制的进展
    • 世界老年人口的增加
  • 市场问题
    • 可能的副作用或过敏反应

波特五力：驾驭慢性特发性便秘药物市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解慢性特发性便秘治疗市场的外部影响

外部宏观环境因素在塑造慢性特发性便秘治疗药物市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析：了解慢性特发性便秘治疗药物市场的竞争格局

对慢性特发性便秘治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 慢性特发性便秘治疗药物市场供应商定位矩阵绩效评估

FPNV 定位矩阵是评估慢性特发性便秘治疗药物市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製慢性特发性便秘治疗药物市场的成功之路

对慢性特发性便秘治疗药物市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 生活方式和饮食的改变
      • 提高患者对成药的使用率
      • 全球医疗费用增加
    • 抑制因素
      • 对慢性特发性便秘的认知与诊断下降
    • 机会
      • 药物输送机制的进展
      • 全球老年人口数量不断增加
    • 任务
      • 可能的副作用和过敏反应
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章慢性特发性便秘治疗药物市场：依药物类别

  • 介绍
  • 膨鬆剂
  • 润肤剂
  • 泻药
  • 渗透剂

第七章慢性特发性便秘治疗药物市场：依给药途径

  • 介绍
  • 口服
  • 胃肠外的

第八章慢性特发性便秘治疗药物市场：按分销管道

  • 介绍
  • 医院药房
  • 网路药房
  • 零售药房

第九章北美及南美慢性特发性便秘治疗市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太慢性特发性便秘治疗药物市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲慢性特发性便秘治疗市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbvie Inc.
  • Albireo Pharma, Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • Chugai Pharmaceuticals Co. Ltd.
  • Ferring BV
  • GlaxoSmithKline Plc
  • Johnson & Johnson Services, Inc.
  • Lantheus Holdings
  • Mallinckrodt Pharmaceuticals
  • Pfizer, Inc.
  • Salix Pharmaceuticals, Inc. by Bausch Health
  • Sanofi SA
  • Takeda Pharmaceutical Company
Product Code: MRR-4311CE1A3392

The Chronic Idiopathic Constipation Therapeutic Market was valued at USD 573.25 million in 2023, expected to reach USD 619.07 million in 2024, and is projected to grow at a CAGR of 8.08%, to USD 987.96 million by 2030.

The Chronic Idiopathic Constipation (CIC) therapeutic market focuses on treatments aimed at relieving prolonged constipation without underlying identifiable causes. This market's scope encompasses a range of pharmaceutical interventions, including laxatives, prokinetic agents, and newer prescription therapies designed to regulate bowel movements and alleviate symptoms. The necessity for CIC therapeutics stems from the significant prevalence of the condition, impacting patient quality of life and burdening healthcare systems. Applications primarily target amelioration of symptoms and prevention of complications, with gastroenterologists and primary care physicians usually spearheading the end-use spectrum through prescription and patient management. Key growth drivers include an aging population more susceptible to chronic constipation and advancements in drug formulations enhancing efficacy and safety profiles. Additionally, increased awareness and diagnosis rates contribute positively to market expansion. However, potential opportunities lie in the development of tailored treatments leveraging biotechnological advances, such as microbiome-modulating therapies or personalized medicine approaches that take into account genetic predispositions. Companies are encouraged to focus R&D efforts on innovative delivery mechanisms and combination therapies to foster patient adherence and improve outcomes. Nevertheless, market growth is constrained by significant challenges, including stringent regulatory frameworks, high research and development costs, and competition from off-label utilization of existing medications. Moreover, the paucity of awareness among physicians regarding newer therapeutic options can limit market penetration. Best innovation areas encompass developing non-systemic therapies with minimized side effects and technologies facilitating real-time monitoring of patient symptoms for more precise treatment adjustments. The CIC therapeutic market is dynamic yet heavily influenced by regulatory policies, competitive pricing, and ongoing clinical trials that shape treatment paradigms. As such, the market landscape necessitates strategic forging of collaborations among drug manufacturers, healthcare providers, and research institutions to accelerate innovative breakthroughs and enhance overall patient care.

KEY MARKET STATISTICS
Base Year [2023] USD 573.25 million
Estimated Year [2024] USD 619.07 million
Forecast Year [2030] USD 987.96 million
CAGR (%) 8.08%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Chronic Idiopathic Constipation Therapeutic Market

The Chronic Idiopathic Constipation Therapeutic Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Change in lifestyle and dietary
    • Higher utilization of OTC drugs by patients
    • Rise in healthcare expenditure across the world
  • Market Restraints
    • Reduced awareness and diagnosis of chronic idiopathic constipation
  • Market Opportunities
    • Progress in drug delivery mechanisms
    • Increase in geriatric population globally
  • Market Challenges
    • Probable side effects and allergic reactions

Porter's Five Forces: A Strategic Tool for Navigating the Chronic Idiopathic Constipation Therapeutic Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Chronic Idiopathic Constipation Therapeutic Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Chronic Idiopathic Constipation Therapeutic Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Chronic Idiopathic Constipation Therapeutic Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Chronic Idiopathic Constipation Therapeutic Market

A detailed market share analysis in the Chronic Idiopathic Constipation Therapeutic Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Chronic Idiopathic Constipation Therapeutic Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Chronic Idiopathic Constipation Therapeutic Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Chronic Idiopathic Constipation Therapeutic Market

A strategic analysis of the Chronic Idiopathic Constipation Therapeutic Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Chronic Idiopathic Constipation Therapeutic Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., Albireo Pharma, Inc., Astellas Pharma Inc., Bayer AG, Chugai Pharmaceuticals Co. Ltd., Ferring B.V., GlaxoSmithKline Plc, Johnson & Johnson Services, Inc., Lantheus Holdings, Mallinckrodt Pharmaceuticals, Pfizer, Inc., Salix Pharmaceuticals, Inc. by Bausch Health, Sanofi S.A., and Takeda Pharmaceutical Company.

Market Segmentation & Coverage

This research report categorizes the Chronic Idiopathic Constipation Therapeutic Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Bulk-Forming Agents, Emollients, Laxatives, and Osmotic Agents.
  • Based on Route of Administration, market is studied across Oral and Parenteral.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Change in lifestyle and dietary
      • 5.1.1.2. Higher utilization of OTC drugs by patients
      • 5.1.1.3. Rise in healthcare expenditure across the world
    • 5.1.2. Restraints
      • 5.1.2.1. Reduced awareness and diagnosis of chronic idiopathic constipation
    • 5.1.3. Opportunities
      • 5.1.3.1. Progress in drug delivery mechanisms
      • 5.1.3.2. Increase in geriatric population globally
    • 5.1.4. Challenges
      • 5.1.4.1. Probable side effects and allergic reactions
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Chronic Idiopathic Constipation Therapeutic Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Bulk-Forming Agents
  • 6.3. Emollients
  • 6.4. Laxatives
  • 6.5. Osmotic Agents

7. Chronic Idiopathic Constipation Therapeutic Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Oral
  • 7.3. Parenteral

8. Chronic Idiopathic Constipation Therapeutic Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Americas Chronic Idiopathic Constipation Therapeutic Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Chronic Idiopathic Constipation Therapeutic Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Chronic Idiopathic Constipation Therapeutic Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbvie Inc.
  • 2. Albireo Pharma, Inc.
  • 3. Astellas Pharma Inc.
  • 4. Bayer AG
  • 5. Chugai Pharmaceuticals Co. Ltd.
  • 6. Ferring B.V.
  • 7. GlaxoSmithKline Plc
  • 8. Johnson & Johnson Services, Inc.
  • 9. Lantheus Holdings
  • 10. Mallinckrodt Pharmaceuticals
  • 11. Pfizer, Inc.
  • 12. Salix Pharmaceuticals, Inc. by Bausch Health
  • 13. Sanofi S.A.
  • 14. Takeda Pharmaceutical Company

LIST OF FIGURES

  • FIGURE 1. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET RESEARCH PROCESS
  • FIGURE 2. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET DYNAMICS
  • TABLE 7. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY BULK-FORMING AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY EMOLLIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LAXATIVES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY OSMOTIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET, FPNV POSITIONING MATRIX, 2023